Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
812
Change from baseline in the last 6-hr mean DBP & SBP as measured by ABPM at the end of and 8-wk treatment period (T80 vs R5 mg) and 14-wk treatment period (T80 vs R10 mg)
Time frame: Up to week 14
Change from baseline in last 6-hr ABPM mean for: pulse pressure; DBP, SBP and PP; DBP/SBP/PP in the morning, daytime and nighttime periods of the 24-hr dosing interval; Change from baseline in mean, seated, trough DBP & SBP measured by manual cuff
Time frame: Up to week 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
Harold B. Betton, M.D.
Little Rock, Arkansas, United States
Attn: Ginger Paselk
Long Beach, California, United States
Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
Boehringer Ingelheim Investigational Site
Orange, California, United States
Boehringer Ingelheim Investigational Site
San Diego, California, United States
Boehringer Ingelheim Investigational Site
Santa Ana, California, United States
Boehringer Ingelheim Investigational Site
Santa Rosa, California, United States
...and 64 more locations